Company news
Halozyme Therapeutics, Inc. news in 2022
Halozyme Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Halozyme reports third quarter 2022 financial and operating results
November 7, 2022
Halozyme to Report Third Quarter 2022 Financial and Operating Results
October 24, 2022
Halozyme to Participate in the 2022 Wells Fargo Healthcare Conference
August 31, 2022
Halozyme Therapeutics, Inc. Announces Upsize and Pricing of Private Offering of $625 Million of Convertible Senior Notes due 2028
August 14, 2022
Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2028
August 14, 2022
Halozyme reports second quarter 2022 financial and operating results
August 8, 2022
Positive Results Announced from Phase III IMscin001 Study Evaluating Subcutaneous Formulation of Tecentriq® with ENHANZE® in Advanced Non-Small Cell Lung Cancer
August 1, 2022
Halozyme to Report Second Quarter 2022 Financial and Operating Results
July 25, 2022
Halozyme to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
June 7, 2022
Halozyme Announces Commercial Launch of TLANDO™, an Oral Treatment for Testosterone Replacement Therapy
June 6, 2022
Halozyme Completes Antares Pharma Acquisition
May 23, 2022
Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma
May 11, 2022
Halozyme Reports First Quarter 2022 Results
May 9, 2022
Halozyme To Host First Quarter 2022 Financial Results Webcast and Conference Call
May 2, 2022
Halozyme commences tender offer for all outstanding shares of common stock of antares pharma
April 25, 2022
Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader
April 12, 2022
Halozyme Therapeutics, Inc. and Chugai Pharmaceutical Enter Global Collaboration and License Agreement for ENHANZE® Technology
March 23, 2022
Positive Topline Results Announced from ADAPT-SC Study Evaluating Subcutaneous Efgartigimod Using ENHANZE® Drug Delivery Technology for Generalized Myasthenia Gravis
March 21, 2022
Halozyme Appoints Moni Miyashita to Board of Directors
March 14, 2022
Halozyme reports fourth quarter 2021 and full year results
February 21, 2022
Halozyme to host fourth quarter and full year 2021 financial results webcast and conference call
February 8, 2022
Halozyme Appoints New Chief Financial Officer
February 1, 2022
Halozyme provides 2022 financial guidance and outlook
January 9, 2022
Halozyme to Present Virtually at the 40th Annual J.P. Morgan Health Care Conference
January 3, 2022
Calls in 2022
- Halozyme Therapeutics (NASDAQ:HALO) Q3 2022 Earnings Call
Nov 8, 2022
Transcript - Halozyme Therapeutics (NASDAQ:HALO) Q2 2022 Earnings Call
Aug 9, 2022
Transcript - Halozyme Therapeutics (NASDAQ:HALO) Q1 2022 Earnings Call
May 10, 2022
Transcript - Halozyme Therapeutics (NASDAQ:HALO) Q4 2021 Earnings Call
Feb 22, 2022
Transcript
Decks in 2022
- Q3 2022 Earnings Presentation
Earnings · 17 slides · Nov 8, 2022
- Q2 2022 Earnings Presentation
Earnings · 17 slides · Aug 9, 2022
- Q1 2022 Earnings Presentation
Earnings · 19 slides · May 10, 2022
- Merger or Acquisition (April 2022)
Merger or acquisition · 20 slides · Apr 13, 2022
- FY2021 Earnings Presentation
Earnings · 15 slides · Feb 22, 2022
- 40th Annual J.P. Morgan Healthcare Conference (January 2022)
Conference · 30 slides · Jan 10, 2022